(IBIE) iShares Trust - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46438G7034 • Target Maturity

IBIE: Inflation-Protected, Treasury, Securities, Target, Maturity

The iShares Trust (NYSE ARCA:IBIE) is an exchange-traded fund (ETF) that tracks an index comprising U.S. Treasury Inflation-Protected Securities (TIPS) maturing between January 1, 2028, and October 15, 2028. This ETF is designed to provide investors with exposure to a specific segment of the TIPS market, focusing on securities with maturities within a relatively narrow window.

As a Target Maturity ETF, IBIE is structured to mature at a specific date, allowing investors to plan their investments according to their financial goals or liabilities. The fund invests at least 80% of its assets in the component securities of its underlying index, ensuring a high degree of alignment with the indexs performance.

Analyzing the ETFs technical data, we observe a stable price action with the last price being $26.10, closely aligned with its 20-day Simple Moving Average (SMA) of $26.11. The 50-day SMA at $25.98 and 200-day SMA at $25.43 indicate a generally positive trend, with the shorter-term averages above the longer-term average. The Average True Range (ATR) of 0.07, or 0.27%, suggests relatively low volatility.

From a fundamental perspective, the Assets Under Management (AUM) stand at $85.95 million, indicating a moderate level of investor interest in the fund. Given the current interest rate environment and inflation expectations, TIPS are generally attractive to investors seeking protection against inflation.

Forecasting the performance of IBIE based on both technical and fundamental data, we can infer that the ETF is likely to continue its stable trend. The proximity of the current price to the 52-week high of $26.27 and the relatively low ATR suggest that significant price movements are unlikely in the short term. However, as the underlying TIPS approach maturity and with the current inflationary pressures, there might be a slight upward bias in the price due to the inherent inflation protection offered by TIPS. Therefore, it is reasonable to expect that IBIE could maintain its current levels or slightly appreciate as it continues to track its underlying index closely.

Additional Sources for IBIE ETF

IBIE ETF Overview

Market Cap in USD 86m
Category Target Maturity
TER 0.10%
IPO / Inception 2023-09-13

IBIE ETF Ratings

Growth Rating 51.3
Fundamental -
Dividend Rating 53.9
Rel. Strength -3.74
Analysts -
Fair Price Momentum 27.34 USD
Fair Price DCF -

IBIE Dividends

Dividend Yield 12m 4.51%
Yield on Cost 5y 4.91%
Annual Growth 5y 137.46%
Payout Consistency 66.7%

IBIE Growth Ratios

Growth Correlation 3m 83.8%
Growth Correlation 12m 90.5%
Growth Correlation 5y 96.5%
CAGR 5y 6.28%
CAGR/Max DD 5y 3.70
Sharpe Ratio 12m 1.60
Alpha 2.76
Beta -0.003
Volatility 2.78%
Current Volume 15.4k
Average Volume 20d 7.9k
What is the price of IBIE stocks?
As of May 22, 2025, the stock is trading at USD 26.04 with a total of 15,398 shares traded.
Over the past week, the price has changed by +0.20%, over one month by +0.12%, over three months by +1.98% and over the past year by +6.94%.
Is iShares Trust a good stock to buy?
Partly, yes. Based on ValueRay Analyses, iShares Trust (NYSE ARCA:IBIE) is currently (May 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 51.32 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBIE as of May 2025 is 27.34. This means that IBIE is currently overvalued and has a potential downside of 4.99%.
Is IBIE a buy, sell or hold?
iShares Trust has no consensus analysts rating.
What are the forecast for IBIE stock price target?
According to ValueRays Forecast Model, IBIE iShares Trust will be worth about 29.5 in May 2026. The stock is currently trading at 26.04. This means that the stock has a potential upside of +13.4%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 29.5 13.4%